Business Context and Reporting Period
Rein Therapeutics, Inc. (RNTX) filed a Form 8-K on August 21, 2026, reporting a significant corporate event regarding its listing status on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on compliance with listing standards.
Material Changes
The Company received a notice of delisting from the Nasdaq Stock Market, LLC, due to non-compliance with Rule 5550(a)(1). The closing bid price of the Company's common stock fell below $1.00 per share for 30 consecutive trading days prior to the notice date.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 days from the notice date (until February 17, 2027) to regain compliance.
- Requirement: The stock must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
- Extension Possibility: If compliance is not met within the initial 180 days, the Company may be eligible for additional time, contingent upon meeting other listing standards (e.g., market value of publicly held shares) and providing specific undertakings to Nasdaq.
- Risk of Delisting: There is no assurance that additional time will be granted. Failure to regain compliance in a timely manner will result in the commencement of suspension and delisting procedures.
Investor Verification Checklist
- Verify the current trading price of RNTX to assess the gap from the $1.00 threshold.
- Monitor the Company's stock price daily to track progress toward the 10 consecutive day requirement.
- Review future filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Check for updates on the Company's market value of publicly held shares to determine eligibility for a potential extension period.